Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

IRLAB Therapeutics

2.32 SEK

-1.07 %

Less than 1K followers

IRLAB A

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.07 %
-3.73 %
-13.91 %
-65.34 %
-77.14 %
-80.42 %
-93.84 %
-94.23 %
-78.81 %

IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.

Read more
Market cap
197.06M SEK
Turnover
115.67K SEK
Revenue
94.63M
EBIT %
-79.37 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2026

Annual report '25

6/5
2026

Interim report Q1'26

20/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press release11/27/2025, 6:00 AM

IRLAB medverkar på Redeye Technology & Life Science Day den 3 december 2025

IRLAB Therapeutics
Press release11/27/2025, 6:00 AM

IRLAB participates in Redeye Technology & Life Science Day on December 3, 2025

IRLAB Therapeutics
Regulatory press release11/20/2025, 3:40 PM

Valberedningen utsedd inför IRLAB:s årsstämma 2026

IRLAB Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/20/2025, 3:40 PM

Nomination committee appointed for IRLAB’s annual general meeting 2026

IRLAB Therapeutics
Press release11/7/2025, 6:00 AM

IRLAB receives acceptance for two abstracts at AD/PD™ 2026: The 20th International Conference on Alzheimer’s and Parkinson’s Diseases

IRLAB Therapeutics
Press release11/7/2025, 6:00 AM

IRLAB får två abstracts accepterade till AD/PD™ 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar

IRLAB Therapeutics
Press release11/4/2025, 12:51 PM

Redeye: IRLAB Therapeutics (Q3 review) - Approaching study initiation

IRLAB Therapeutics
Regulatory press release10/29/2025, 6:00 AM

IRLAB publicerar delårsrapport för perioden januari – september 2025

IRLAB Therapeutics
Regulatory press release10/29/2025, 6:00 AM

IRLAB publishes interim report for the period January - September 2025

IRLAB Therapeutics
Press release10/23/2025, 5:00 AM

IRLAB: Inbjudan till presentation och webcast av delårsrapport för det tredje kvartalet 2025

IRLAB Therapeutics
Press release10/23/2025, 5:00 AM

IRLAB: Invitation to the interim report for Q3 2025 presentation and webcast

IRLAB Therapeutics
Regulatory press release10/9/2025, 3:15 PM

IRLAB utser Gustaf Albèrt till ny Chief Financial Officer

IRLAB Therapeutics
Regulatory press release10/9/2025, 3:15 PM

IRLAB appoints Gustaf Albèrt as the new Chief Financial Officer.

IRLAB Therapeutics
Press release10/9/2025, 5:00 AM

IRLAB presenterar på Redeye Theme: Neurology

IRLAB Therapeutics
Press release10/9/2025, 5:00 AM

IRLAB to present at Redeye Theme: Neurology

IRLAB Therapeutics
Press release10/2/2025, 5:00 AM

IRLAB avancerar den fullt finansierade studien av IRL757 vid Parkinsons sjukdom i samarbete med MSRD

IRLAB Therapeutics
Press release10/2/2025, 5:00 AM

IRLAB progresses fully funded IRL757 study in Parkinson’s Disease in partnership with MSRD

IRLAB Therapeutics
Press release9/4/2025, 5:00 AM

IRLAB beviljas patent som stärker marknadsexklusiviteten för läkemedelskandidaten mesdopetam i Kina

IRLAB Therapeutics
Press release9/4/2025, 5:00 AM

IRLAB is granted a patent strengthening the market exclusivity of the drug candidate mesdopetam in China

IRLAB Therapeutics
Press release9/1/2025, 9:13 AM

Redeye: IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials

IRLAB Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.